Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 88 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.04 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $485 | -3.6% | 89,000 | +20.1% | 0.00% | 0.0% |
Q2 2023 | $503 | -77.5% | 74,100 | -83.4% | 0.00% | -33.3% |
Q1 2023 | $2,235 | +317.0% | 446,400 | +306.2% | 0.00% | +50.0% |
Q4 2022 | $536 | -99.9% | 109,900 | +277.7% | 0.00% | 0.0% |
Q3 2022 | $419,000 | +4.2% | 29,100 | +9.4% | 0.00% | 0.0% |
Q2 2022 | $402,000 | +34.9% | 26,600 | +6.0% | 0.00% | +100.0% |
Q1 2022 | $298,000 | -35.1% | 25,100 | +65.1% | 0.00% | -50.0% |
Q1 2021 | $459,000 | -32.8% | 15,200 | +10.1% | 0.00% | -33.3% |
Q4 2020 | $683,000 | +29.1% | 13,800 | 0.0% | 0.00% | +50.0% |
Q3 2020 | $529,000 | -27.9% | 13,800 | -18.8% | 0.00% | -33.3% |
Q2 2020 | $734,000 | +19.3% | 17,000 | -28.0% | 0.00% | 0.0% |
Q1 2020 | $615,000 | -16.6% | 23,600 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $737,000 | -35.9% | 23,600 | -46.6% | 0.00% | 0.0% |
Q3 2019 | $1,150,000 | +2574.4% | 44,200 | +2226.3% | 0.00% | – |
Q2 2019 | $43,000 | -12.2% | 1,900 | 0.0% | 0.00% | – |
Q1 2019 | $49,000 | +28.9% | 1,900 | 0.0% | 0.00% | – |
Q4 2018 | $38,000 | – | 1,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |